144 related articles for article (PubMed ID: 38644469)
1. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
Ghilardi G; Paruzzo L; Patel V; Svoboda J; Chong ER; Fardella E; Chong EA; Gabrielli G; Nasta SD; Landsburg DJ; Carter J; Pajarillo R; Barta SK; White G; Weber E; Napier E; Porter DL; Garfall AL; Schuster SJ; Ruella M
J Hematol Oncol; 2024 Apr; 17(1):19. PubMed ID: 38644469
[TBL] [Abstract][Full Text] [Related]
2. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Makita S; Yamamoto G; Maruyama D; Asano-Mori Y; Kaji D; Ananthakrishnan R; Ogasawara K; Stepan L; Schusterbauer C; Rettby N; Hasskarl J; Izutsu K
Cancer Med; 2022 Dec; 11(24):4889-4899. PubMed ID: 35619325
[TBL] [Abstract][Full Text] [Related]
4. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.
Maloney DG; Kuruvilla J; Liu FF; Kostic A; Kim Y; Bonner A; Zhang Y; Fox CP; Cartron G
J Hematol Oncol; 2021 Sep; 14(1):140. PubMed ID: 34493319
[TBL] [Abstract][Full Text] [Related]
5. Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
Ong SY; Pak S; Mei M; Wang Y; Popplewell L; Baird JH; Herrera AF; Shouse G; Nikolaenko L; Zain J; Godfrey J; Htut M; Aribi A; Spielberger R; Mansour J; Forman SJ; Palmer J; Budde LE
Am J Hematol; 2023 Nov; 98(11):1751-1761. PubMed ID: 37668287
[TBL] [Abstract][Full Text] [Related]
6. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas.
Ghilardi G; Chong EA; Svoboda J; Wohlfarth P; Nasta SD; Williamson S; Landsburg JD; Gerson JN; Barta SK; Pajarillo R; Myers J; Chen AI; Schachter L; Yelton R; Ballard HJ; Hodges Dwinal A; Gier S; Victoriano D; Weber E; Napier E; Garfall A; Porter DL; Jäger U; Maziarz RT; Ruella M; Schuster SJ
Ann Oncol; 2022 Sep; 33(9):916-928. PubMed ID: 35690221
[TBL] [Abstract][Full Text] [Related]
7. Lisocabtagene Maraleucel in Relapsed or Refractory Diffuse Large B Cell Lymphoma: What is the Evidence?
Kharfan-Dabaja MA; Yassine F; Moustafa MA; Iqbal M; Murthy H
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(4):168-175. PubMed ID: 34699774
[TBL] [Abstract][Full Text] [Related]
8. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
St-Pierre F; Gordon LI
Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States.
Parker C; Liu FF; Deger KA; Franco-Villalobos C; Proskorovsky I; Keating SJ; Sorensen S
Adv Ther; 2023 May; 40(5):2355-2374. PubMed ID: 36947328
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
[TBL] [Abstract][Full Text] [Related]
12. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS;
Lancet; 2022 Jun; 399(10343):2294-2308. PubMed ID: 35717989
[TBL] [Abstract][Full Text] [Related]
13. Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis.
Yamshon S; Gribbin C; Alhomoud M; Chokr N; Chen Z; Demetres M; Pasciolla M; Leonard J; Shore T; Martin P
Clin Lymphoma Myeloma Leuk; 2024 Feb; ():. PubMed ID: 38582666
[TBL] [Abstract][Full Text] [Related]
14. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.
Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Ogasawara K; Kamdar M
Blood; 2023 Apr; 141(14):1675-1684. PubMed ID: 36542826
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma.
Ogasawara K; Lymp J; Mack T; Dell'Aringa J; Huang CP; Smith J; Peiser L; Kostic A
Clin Pharmacol Ther; 2022 Jul; 112(1):81-89. PubMed ID: 35156195
[TBL] [Abstract][Full Text] [Related]
16. Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study.
Wang M; Siddiqi T; Gordon LI; Kamdar M; Lunning M; Hirayama AV; Abramson JS; Arnason J; Ghosh N; Mehta A; Andreadis C; Solomon SR; Kostic A; Dehner C; Espinola R; Peng L; Ogasawara K; Chattin A; Eliason L; Palomba ML
J Clin Oncol; 2024 Apr; 42(10):1146-1157. PubMed ID: 38072625
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement.
Yi D; Gergis M; Elgohary G; Hsu J; Yang Y; Bi X; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):66-72. PubMed ID: 36537908
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.
Ghilardi G; Paruzzo L; Svoboda J; Chong EA; Shestov AA; Chen L; Cohen IJ; Gabrielli G; Nasta SD; Porazzi P; Landsburg DJ; Gerson JN; Carter J; Barta SK; Yelton R; Pajarillo R; Patel V; White G; Ballard HJ; Weber E; Napier E; Chong ER; Fraietta JA; Garfall AL; Porter DL; Milone MC; O'Connor R; Schuster SJ; Ruella M
Blood Adv; 2024 Feb; 8(3):653-666. PubMed ID: 38113468
[TBL] [Abstract][Full Text] [Related]
19. Next-Generation Chimeric Antigen Receptor T-cells.
Yi D; Gergis M; Hsu J; Yang Y; Bi X; Aljurf M; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):117-121. PubMed ID: 36537905
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
